Last updated on October 2017

A Phase III, randomized, double-blind, placebo controlled, multicenter study to evaluate the efficacy and safety of Etrolizumab as an induction and maintenance treatment for patients with moderately to severe active Crohn's Disease.


Brief description of study

A Phase III, randomized, double-blind, placebo controlled, multicenter study to evaluate the efficacy and safety of Etrolizumab as an induction and maintenance treatment for patients with moderately to severe active Crohn's Disease.

Detailed Study Description

This is a multicenter, Phase III, double-blind, placebo-controlled study evaluating the safety and efficacy of etrolizumab during induction and maintenance treatment of moderate to severely active Crohn's disease (CD) in patients who are anti-tumor necrosis factor (TNF) naive (TNF-naive) and in patients who are refractory or intolerant of tumor necrosis factor inhibitors.

Clinical Study Identifier: TX153721

Contact Investigators or Research Sites near you

Start Over

Kathleen Santiago

Gastro Florida
Clearwater, FL USA
7.65miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.